Clinical trials
Completed Obesity trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
150 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2004 | 3 |
| 2005 | 5 |
| 2006 | 1 |
| 2007 | 6 |
| 2008 | 7 |
| 2009 | 11 |
| 2010 | 3 |
| 2011 | 10 |
| 2012 | 16 |
| 2013 | 12 |
| 2014 | 7 |
| 2015 | 10 |
| 2016 | 2 |
| 2017 | 7 |
| 2018 | 14 |
| 2019 | 5 |
| 2020 | 6 |
| 2021 | 8 |
| 2022 | 6 |
| 2023 | 7 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 150 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Maastricht University Medical Center | 54 |
| Novo Nordisk A/S | 11 |
| TNO | 9 |
| Rijnstate Hospital | 8 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 6 |
| Amsterdam UMC, location VUmc | 6 |
| Wageningen University | 5 |
| Boehringer Ingelheim | 4 |
| Rhythm Pharmaceuticals, Inc. | 4 |
| Maastricht University | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Obesity | 150 |
| Overweight | 39 |
| Diabetes Mellitus, Type 2 | 29 |
| Insulin Resistance | 22 |
| Glucose Intolerance | 9 |
| Metabolic Syndrome | 7 |
| Nutrition Disorders | 7 |
| Body Weight | 6 |
| Diabetes Mellitus | 6 |
| Weight Loss | 5 |
Trials
Showing 1 to 25 of 150. Each trial links to its page on Pharma Observatory.
50 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.